



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE

Date: 22.07.2024

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe

Please find enclosed herewith our Press Release relating to grant of Marketing Authorization for Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal, Europe to the Wholly owned European Subsidiary of the company.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

ZIM Laboratories Limited
Announces Grant of Marketing Authorization for
Azithromycin for Oral Suspension 200 mg/5ml (40 mg/ml) in Portugal,
Europe

Nagpur, India July 22, 2024:

About ZIM Laboratories Limited

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company which develops, manufactures and supplies differentiated generic products in oral solid dosage forms, across key therapeutic segments. The Company has state of the art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms with the aim of providing patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

The Company is pleased to announce today that INFARMED (Portugal) - The Portuguese National Authority of Medicines and Health Products has granted the Marketing Authorisation (MA) for one of ZIM's New Innovative Products (NIP) " Azithromycin for Oral Suspension 200 mg/5ml " in Portugal to ZIM's wholly owned European Subsidiary – SIA ZIM Laboratories Limited.

This is the 1st Marketing Authorisation (MA) for ZIM for its New Innovative Products (NIP) for Europe. Azithromycin Oral Suspension is differentiated in taste masked suspension dosage form which benefits patients who have difficulty in swallowing and children who have difficulty with bitter taste.

According to IQVIA, the EU market size for this product in 2022 was approx. USD 300Mn. Additionally other target markets for ZIM such as SE Asia & Oceania, Latin America and MENA have a combined market size of approx. USD 900Mn